FDA Approves Novel Glucose Monitoring System
The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.
Related News Articles
Headline
The Drug Enforcement Administration and Department of Health and Human Services Nov. 15 issued a final rule extending certain telemedicine prescribing…
Headline
In comments Nov. 12 to majority and minority leaders of the House and Senate, the AHA requested that Congress act on key priorities for hospitals and health…
Headline
In this conversation, Johnna Nynas, M.D., obstetrician and gynecologist at Sanford Health Bemidji, discusses the dramatic expansion of maternal telehealth…
Headline
The Centers for Medicare & Medicaid Services Nov. 1 released its calendar year 2025 final rule for the physician fee schedule. The rule will cut the…
Perspective
People want medical care that is safe, convenient and accessible. Hospitals deliver that every day within their walls — and increasingly, outside of their…
Headline
The AHA Oct. 4 urged the Drug Enforcement Administration and Department of Health and Human Services to extend telehealth flexibilities an additional two years…